

Mechanisms in endocrinology

Fountas, Athanasios; Chai, Shu Teng; Kourkouti, Chrysoula; Karavitaki, Niki

DOI:

[10.1530/EJE-18-0270](https://doi.org/10.1530/EJE-18-0270)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Fountas, A, Chai, ST, Kourkouti, C & Karavitaki, N 2018, 'Mechanisms in endocrinology: endocrinology of opioids', *European Journal of Endocrinology*, vol. 179, no. 4, pp. R183–R196. <https://doi.org/10.1530/EJE-18-0270>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 26/06/2019

Disclaimer: this is not the definitive version of record of this article. This manuscript has been accepted for publication in *European Journal of Endocrinology*, but the version presented here has not yet been copy-edited, formatted or proofed. Consequently, Bioscientifica accepts no responsibility for any errors or omissions it may contain. The definitive version is now freely available at: <https://doi.org/10.1530/EJE-18-0270> 2018.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 ENDOCRINOLOGY OF OPIOIDS

2
3 Athanasios Fountas^{1,2,3}, Shu Teng Chai^{1,2,3}, Chrysoula Kourkouti^{2,3}, Niki Karavitaki^{1,2,3}

4
5 ¹ *Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University*
6 *of Birmingham, B15 2TT, Birmingham, UK;* ² *Centre for Endocrinology, Diabetes and Metabolism,*
7 *Birmingham Health Partners, Birmingham, B15 2TH, UK;* ³ *Department of Endocrinology, Queen*
8 *Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH,*
9 *UK*

10 11 **Corresponding author:**

12 Dr. Niki Karavitaki, MSc, PhD, FRCP

13 Institute of Metabolism and Systems Research (IMSR), College of Medical and Dental Sciences,
14 University of Birmingham, IBR Tower, Level 2, Birmingham, B15 2TT, UK

15 Tel.: 0121 414 3826

16 Fax: 0121 415 8712 17

17 E-mail: n.karavitaki@bham.ac.uk

18
19 **Short Title:** Effects of opioids on endocrine system

20 **Key words:** opioids, opiates, hypogonadism, hypoadrenalism

21 **Word count:** 4830

Abstract

The use of opioids has grown substantially over the past two decades reaching the dimensions of a global epidemic. These drugs have effects on multiple levels of the endocrine system through mechanisms which are still not fully elucidated, and awareness of their endocrine sequelae is vital for all specialists prescribing or managing patients on them. Hypogonadism is the most well recognised consequence of opioid use (prevalence 21-86%) which, however, may remain undiagnosed with potential adverse outcomes for the patients. Although less frequent, cortisol deficiency can be also found. Furthermore, there is negative impact on bone health (with reduced bone mineral density and increased fracture risk) and occasionally hyperprolactinaemia, whereas the clinical significance of alterations in other hormones remains to be clarified. Discontinuation or reduction of the opioid and, in cases of chronic pain, consideration of alternative therapies for pain relief are potential management options. Hormonal replacement, especially when the above measures are not practically feasible, needs to be considered. Further studies are needed to clearly establish the prevalence of hormonal abnormalities with various regimes, doses and routes of opioids and to address reliably the long-term benefits and risks of hormonal treatment in patients on opioids. Until evidence-based, safe and cost-effective clinical guidelines become available, periodical assessment of the gonadal and adrenal function (particularly when relevant clinical manifestations are present) and evaluation of the bone health status are advised.

Introduction

Opium is acquired in the dried latex form from the seed pod of the opium poppy (*Papaver somniferum*), initially cultivated by the Sumerians at around 4000 BC. The naturally occurring alkaloids of opium and the drugs synthesized from it are described as ‘opiates’, whilst all natural or synthetic chemicals that bind to opioid receptors are included in the term ‘opioids’. The main classes of opioids include natural opiates (alkaloids in the resin of the opium poppy, mainly morphine, codeine and thebaine), esters of morphine [e.g. morphine diacetate or diamorphine (heroin)], semi-synthetic opioids (produced from the natural opiates or morphine esters, e.g. hydromorphone, hydrocodone, oxycodone, oxymorphone, buprenorphine), fully synthetic opioids (e.g. fentanyl, pethidine, methadone, tramadol) and endogenous opioid peptides produced in the body (e.g. endorphins, enkephalins)¹.

Opioids exert their actions by binding to receptors which belong to the family of G-protein coupled ones, and their activation produces a range of different effects¹. There are many types of opioid receptors with the three main being μ , κ , δ (that are naloxone sensitive), whereas the nociceptin receptor, with effects not reversed by naloxone, was discovered in 1994². The opioids used in clinical practice have various indications and are mainly offered as analgesic agents (Table 1), whereas heroin is used as a recreational drug due to its euphoric effects (illicit use). The most commonly available opioids (morphine, codeine, fentanyl, and their derivatives, methadone, tramadol, pethidine) are primarily μ -receptors agonists, whilst buprenorphine and pentazocine are mixed agonists/antagonists³. Pentazocine acts as a partial agonist on δ - and κ -receptors and as an antagonist on the μ -receptor, whilst buprenorphine has partial agonist activity on μ - and nociceptin receptors and antagonist activity on κ -receptors⁴.

The use of opioids has grown over the past two decades; between 2000 and 2014, it increased 216% in USA and 210% globally making opioid consumption a real global epidemic⁵. Notably, in 2014, USA used around 69% of the world’s supply of opioids; prescribers involve a wide range of health professionals including pain physicians, family physicians, orthopaedic surgeons, anaesthesiologists, psychiatrists, physical medicine and rehabilitation specialists⁵. Data from the UK

Clinical Practice Research Datalink confirm a significant rise in strong opioid prescriptions (buprenorphine, fentanyl, morphine and oxycodone) between 2000 and 2010, with the majority administered for non-cancer patients⁶; in this report, the number of strong opioid users increased from 9479 to 53,666 during the study period. In addition, prescription of long-acting opioids in patients with chronic non-cancer pain has been associated with a significantly elevated risk of all-cause and of cardiovascular-specific mortality, compared with analgesic anticonvulsants or low dose tricyclic antidepressants^{5, 7}.

Exogenous opioids can have various effects on the endocrine system, which, nonetheless, may remain underdiagnosed with potential adverse sequelae for the patients. The aim of this manuscript is to provide a review of these effects and their underlying mechanisms, to discuss their clinical significance and management and to identify areas requiring further research in this field.

Hypothalamo-Pituitary-Gonadal axis

Opioids, both endogenous and exogenous, modulate gonadal function primarily by acting on opioid ϵ -receptors in the hypothalamus⁸. This leads to reduced release or disruption of the normal pulsatility of gonadotropin-releasing hormone (GnRH) secretion and reduction of the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH - to a lesser extent) from the pituitary gland, and of testosterone or oestradiol from the gonads⁹⁻¹⁶. Opioids may also directly inhibit the pituitary release of gonadotropins¹⁷. Hyperprolactinaemia that can be occasionally caused by opioids may contribute to their suppressive effects on the HPG axis⁹. Opioids have also direct effects on the gonads: these include decreased production of sperm, testicular interstitial fluid, and intratesticular testosterone¹⁸.

The effects of long-term opioid use on the gonadal status have been studied extensively in the past four decades and the reported prevalence of opioid-induced hypogonadism ranges between 21% and 86%^{10-16, 19}. This wide range is attributed to the heterogeneity of the studies (differences in the populations assessed, variations in the type, dose, route and duration of opioid administration,

potential impact of pain, of other comorbidities and of concurrent medications, and possibly differences in the age of the patients included).

The initial studies involved mainly heroin addicts and patients on methadone for maintenance and had demonstrated reduction of testosterone levels in males, with an associated reduction in LH and/or FSH²⁰⁻²². The decrease in testosterone occurs within a few hours of opioid administration; in a study of 13 males on acetylmethadol for opioid dependence, there was significant reduction of testosterone four hours after the ingestion of the drug, with the levels remaining low around 24 hours after the drug administration and returning to baseline values 48 hours post-acetylmethadol use²³. Woody *et al.* had similar results, albeit the duration of recovery was shorter¹¹. In another study with male heroin addicts, recovery of testosterone to normal occurred after about one month of drug abstinence²¹. Furthermore, methadone has a dose-dependent effect on the testosterone levels of heroin addicts on methadone detoxification²². In female heroin addicts, amenorrhoea and galactorrhoea may be present²⁴; nonetheless, series systematically assessing this group of patients are not available.

Hypogonadism is also present in both male and female patients on opioids (oral, transdermal or intrathecal) for cancerous or non-cancerous pain in cohort or cross-sectional studies; it should be noted, however, that other factors may also contribute to the hypogonadism including pain pathophysiology, pain comorbidities and patients' age and these need to be taken into account when interpreting their results^{12-14, 16, 25-29}. The effects on the HPG axis begin as soon as the opioid is taken^{12, 13, 16, 30} and the hormonal changes are dose-related^{13, 31}. The resultant clinical manifestations include erectile dysfunction, decreased libido, infertility, fatigue, depression, hot flushes and night sweats in males^{13, 16, 27-29} and reduced libido, amenor- or oligomenorrhoea with anovulation in premenopausal females¹⁶. In postmenopausal women, LH and FSH levels can be decreased¹⁶. The prevalence of hypogonadism is higher in men than in women taking oral opioids for chronic non-cancer pain¹⁵. In premenopausal chronic pain patients, the suppression of LH may be less profound when opioids are administered orally/transdermally compared with the intrathecal route⁹. Notably, chronic use of long-acting opioids is associated with greater odds of androgen deficiency compared to chronic use of short-acting ones^{31, 32}. Furthermore, transdermal fentanyl, methadone, and oxycodone (long- and short-acting formulations combined) are associated with higher odds of androgen deficiency when

140 compared to hydrocodone³³. It should be pointed out, however, that these findings reflect the
141 observations at the doses used for different opioids in the various studies. Buprenorphine, a partial μ -
142 receptor agonist and κ -receptor antagonist used as maintenance for opioid dependence or for the
143 management of acute/persistent pain results in less severe hypogonadism when compared to
144 methadone^{34, 35}. Reduction in the dose or cessation of therapy reverses the hypogonadism^{26, 30, 36, 37} but
145 the time course of this has not been systematically studied.

146 Despite the abundance of evidence indicating that opioids lead to hypogonadotropic
147 hypogonadism, this condition remains underdiagnosed in daily practice; this may relate with lack of
148 symptoms reporting by the patients combined with the underappreciation of this common problem
149 amongst the clinicians. Currently, there is no consensus or clinical guidelines for the diagnosis and
150 management of opioid-induced hypogonadism. Manifestations of hypogonadism should be enquired
151 before, as well as during opioid treatment and patients should be educated on this potential side effect
152 and encouraged to report hypogonadal symptoms should they experience any. Laboratory evaluations
153 need to be taken periodically (and also when changing dose or regime of opioid) and include
154 measurement of blood testosterone (in a morning sample before 10 am) and gonadotropins in men and
155 oestradiol and gonadotropins in women (combined with menstrual history)³⁸. Measurement of
156 prolactin (PRL) and taking into account the impact of other medications and co-morbidities, as well as
157 exclusion of other causes of hypogonadotropic hypogonadism are also advised.

158 Management of the opioid-induced hypogonadism includes discontinuation or reduction of the
159 dose of the opioid and consideration of alternative therapies for patients on chronic pain requiring
160 pain relief. When the above measures are not viable, gonadal hormone replacement should be
161 considered with a number of studies showing beneficial effects. Aloisi *et al.*, in a series of nine males
162 (aged between 44 and 75 years) on epidural morphine for non-oncological chronic pain treated with
163 testosterone gel for 12 months, demonstrated improvement in the sexual dimension of the Aging
164 Males' Symptoms scale and in the Mental Index of the SF-36 questionnaire³⁹. The patients also
165 reported increase in the growth of body hair and improved appetite and their prostate-specific antigen
166 (PSA) levels remained within normal limits. None of the Profile of Mood State subscale scores or
167 Centre for Epidemiological Studies Depression Scale ratings showed significant changes³⁹. Daniell *et*

168 *al.*, in an open-label pilot study on 16 men (aged between 34 and 55 years) with opioid-induced
169 androgen deficiency (on oral sustained release oxycodone or oral methadone for pain syndromes)
170 offered testosterone transdermal patches for 24 weeks, found improvement in androgen deficiency
171 symptoms, sexual function, psychological well-being and depressed mood by using validated
172 questionnaires, as well as of the haemoglobin and haematocrit⁴⁰. Basaria *et al.*, in a randomised,
173 double-blind, parallel placebo-controlled trial of 65 males (aged between 18 and 64 years) with
174 opioid-induced androgen deficiency and chronic non-cancer pain, randomised to receive transdermal
175 testosterone or placebo for 14 weeks, found that men in the testosterone arm demonstrated greater
176 improvement in mechanical and pressure hyperalgesia and in sexual desire, as well as reduction in fat
177 mass⁴¹; elevation in PSA >4 ng/ml was seen in two patients, one in each group, and erythrocytosis
178 occurred in neither group. Notably, Huang *et al.*, in a placebo-controlled, double-blind randomized
179 trial from the same centre of 64 non-diabetic men (aged between 18 and 64 years) on opioid
180 analgesics for chronic non-cancer pain and morning total testosterone <12 nmol/L (as measured by
181 liquid chromatography-tandem mass spectrometry), randomised to 14 weeks of transdermal
182 testosterone gel or placebo gel daily, found that changes in lipid profile, fasting glucose and insulin,
183 homeostatic model assessment for insulin resistance and C-reactive protein were similar from baseline
184 to the end of treatment in both groups; glucose and insulin response to 75 gr oral glucose load,
185 inflammatory markers and adipokines also did not differ between the two groups⁴². However, the
186 duration of this study was not long enough to evaluate cardiovascular safety of testosterone therapy in
187 these patients. In contrast to their male counterparts, series looking at gonadal hormone replacement
188 in opioid-induced hypogonadism in women are not available.

189 In summary, opioid use has an inhibitory effect on the HPG axis through action at various levels
190 leading to hypogonadism. Discontinuation or reduction in the dose of opioid can reverse this sequela
191 but when this is not possible, gonadal hormone treatment needs to be considered. Adequately powered
192 well-designed studies are needed to establish the long-term benefits and risks of hormone replacement
193 in this group of patients, as well as the potential impact of hormonal treatment on pain sensitivity and
194 on the recovery of patients on methadone for opioid use disorder.

Hypothalamo-pituitary-adrenal axis

Opioids suppress the HPA axis mainly at the hypothalamic-pituitary level by inhibiting corticotropin-releasing hormone (CRH) and vasopressin secretion and by reducing their effect on adrenocorticotrophic hormone (ACTH) and cortisol release⁴³⁻⁴⁷. The receptors involved are not entirely known but κ - are considered to be the predominant type; δ -receptors have also been implicated^{8, 48, 49}. Nonetheless, the increasing evidence of secondary adrenal insufficiency in patients receiving μ -receptor agonists suggests a potential role of this subtype in the opioid-induced regulation of HPA axis (morphine, hydromorphone, methadone, tramadol, diamorphine, fentanyl and loperamide act predominantly through this receptor)^{36, 37, 50-54}. This is also supported by the observation that human subjects carrying the A118G single nucleotide polymorphism of the μ -receptor encoding gene *OPRM1* (which has been shown to increase the receptor's binding affinity to β -endorphin) show blunted ACTH response to metyrapone and exaggerated cortisol release to naloxone^{55, 56}. Opioids have also direct effects on the adrenal glands, independently of their effect on the hypothalamo-pituitary unit; naloxone administration in patients with hypothalamo-pituitary disconnection led to higher cortisol (but not ACTH) levels compared with saline⁵⁷ and β -endorphin suppressed ACTH-stimulated cortisol production in isolated human adrenocortical cells⁵⁸.

Acute administration of opioids in animals results in an exaggerated response of the HPA axis which may be followed by a rebound decrease of its activity^{59, 60}. Data from animal studies assessing the effects of chronic administration of opioids on ACTH and glucocorticoid release are conflicting showing activation⁶¹, suppression⁵⁹ or no effect⁶².

Single administration of various opioids (morphine, heroin, buprenorphine, remifentanyl) in normal subjects results in suppression of ACTH and glucocorticoid secretion, blunted pituitary-adrenal response to CRH, and diminished cortisol response to psychosocial or surgical stress^{45, 46, 63-65}. Notably, gender may play a role in the effect of opioids on the HPA axis. Women demonstrate a greater sensitivity to opioid receptor antagonists (naloxone and naltrexone) on their cortisol response compared to men suggesting sex differences in the endogenous opioid system⁶⁶⁻⁶⁸. Menstrual cycle

may also be implicated with a study showing that women in the luteal phase of their cycle had greater naltrexone-induced increases in serum cortisol than women in the early follicular phase⁶⁹.

In addition, diacetylmorphine has an acute suppressive effect on HPA axis in heroin dependent addicts on heroin-assisted treatment⁷⁰. Opioid dependent patients on maintenance treatment with intravenous diacetylmorphine have reduced serum levels of vasopressin and cortisol compared to healthy controls⁴³. It is of note that in heroin addicts there is a disturbed cortisol circadian rhythm with lower morning cortisol levels compared with controls^{65, 71}.

Several case reports documenting secondary adrenal insufficiency after oral or transdermal opioid administration of variable duration (including even of a few days) mainly for pain relief have been published^{36, 37, 50-54}. The accurate prevalence of adrenal insufficiency in these patients has not been clearly defined and chronic pain can be a major confounder (chronic pain has been associated with loss of the diurnal variation of blood cortisol, lower morning blood cortisol and 24-hour urinary free cortisol levels compared with controls and hyper-reactive ACTH release to CRH stimulation)^{72, 73}.

Aloisi *et al.* showed that intrathecal administration of morphine (0.9 mg/day) for 15 days in patients with persistent severe pain led to reduction in the blood cortisol levels with an immediate effect from Day 1 to Day 15 in both sexes; the levels rose on Day 16, 24 hours after the opioid withdrawal³⁰. In contrast, transdermal buprenorphine (35mcg/h every 72 hours) for acute/persistent pain for six months did not inhibit the HPA axis. Gibb *et al.*, in a series of 48 patients attending chronic tertiary pain clinics and treated with long-term opioid analgesia (tramadol, oxycodone, morphine sulphate, fentanyl or buprenorphine patch, dihydrocodeine – median daily opioid dose 68 mg as determined by morphine sulphate equivalent dose) for at least 6 months and no recent exposure to exogenous glucocorticoids, found 8.00 am blood cortisol <100 nmol/L in 8% of them and failure to respond to synthetic ACTH stimulation (peak cortisol <430 nmol/l) in 6%⁷⁴. When focusing on the 33 patients on high-dose opioid analgesia (excluding tramadol and dihydrocodeine), approximately 10% of those assessed had an initial suboptimal cortisol response to synthetic ACTH. Intrathecal administration of morphine or hydromorphone in 72 patients with non-malignant pain (mean daily dose 4.8 ± 3.2 mg and mean duration of treatment 26.6 ± 16.3 months) resulted in basal cortisol levels <5 µg/dl and peak cortisol value <18 µg/dl during an insulin tolerance test (ITT) in 9% and 15% of them, respectively¹⁶;

one of the patients in this series developed Addisonian crisis during pneumonia. Furthermore, 33% of 20 chronic pain patients receiving chronic pump intrathecal morphine infusion (0.2-10 mg/day) and 50% of 20 patients on oral morphine (60-120 mg/day) demonstrated hypoadrenalism (defined as stimulated cortisol levels during ITT $<18 \mu\text{g/dl}$)⁷⁵. Additionally, there is reduction of the adrenal androgen dehydroepiandrosterone sulfate levels during opioid therapy in patients with chronic non-malignant pain^{14, 75, 76}. Factors predicting the development of abnormal cortisol stress response are not as yet established. However, given, the widespread use of opioids, it is anticipated that a large number of patients are possibly at risk of cortisol deficiency.

The altered HPA axis function of opioid users improves or returns to normal after discontinuation or reduction in the dose of the drug^{36, 37, 50, 51, 53, 54} but the time interval of this has not been systematically studied. Interestingly, N enke *et al.*, in a pilot, randomized, double-blind, placebo-controlled crossover study with 17 patients on long-term opioid therapy for chronic non-cancer pain and mild hypocortisolism (defined by a plasma cortisol response $\leq 350 \text{ nmol/L}$ at 60 min following a cold pressor test), found that hydrocortisone therapy (10 mg/m²/day) led to improvement in vitality and pain tolerance compared to placebo⁷⁷.

In summary, opioids exert inhibitory actions on the HPA axis by acting at various levels. Although it could be argued that hypocortisolism is an adaptive response to opioids, the reported cases of improvement of clinical manifestations resembling those of cortisol deficiency after glucocorticoid administration^{52, 53, 74, 77} and the description of Addisonian crises whilst on these agents^{16, 54} suggest that, at least in some patients, hypocortisolism is of clinical significance. Further studies are needed to define the prevalence of hypoadrenalism with different opioids at various regimes and routes, to establish the clinical significance and potential consequences/adverse outcomes of the biochemical findings (particularly if these reflect modest changes in the HPA axis) and to provide clear guidance on the reversibility and the time course of the hormonal changes following withdrawal or reduction of opioid dose. Although the existing literature cannot provide robust evidence for safe and cost-effective clinical guidelines, patients on opioids should be considered at risk of hypoadrenalism and checking an early morning plasma cortisol (particularly in the presence of relevant clinical manifestations) is a sensible approach. Further dynamic assessment of the HPA axis will depend on

the results of the basal cortisol. The frequency of the HPA axis assessment is not known but certainly the presence of symptoms/signs of cortisol deficiency should prompt investigations towards this direction.

Somatotroph axis

In animal models, acute opioid administration stimulates growth hormone (GH) secretion^{78, 79}. On the other hand, chronic administration has led to no^{61, 80} or to stimulatory effect⁸¹. Studies on the pathways and mechanisms involved on the effects of opioids on GH release show that various types of opioid receptors (μ , κ , δ) are implicated, but their activation effects vary between reports⁸²⁻⁸⁴. A reset of the hypothalamic GH pulse generator via opioid receptor stimulation is also a possible mechanism⁸⁵. Treatment of rats with antiserum against GHRH inhibited the GH stimulatory response to different types of opiates^{86, 87}. In addition, opioids exert inhibitory effect on somatostatin release⁸⁸ and action⁸⁹. Finally, chronic treatment with morphine decreased GH mRNA levels in rat pituitary and concomitant administration of naloxone inhibited this⁹⁰. Notably, gender may influence the effects of these drugs on the GH secretory dynamics. Continuous morphine exposure of male rats resulted in increased basal and mean GH concentrations, as well as in a modest increase of the GH pulse frequency but not of pulse amplitude; in females, morphine, apart from a marked reduction in the pulse amplitude, had little effect on other parameters of GH secretion⁹¹.

In human subjects, there are acute stimulatory effects of opioids on GH secretion which relate with the dose offered^{92, 93}. Thus, intravenous morphine at doses of 5 mg and 10 mg did not promote GH secretion but a higher dose of 15 mg did^{92, 94, 95}. Notably, administration of a Met-enkephalin analogue G-DAMME, in healthy men combined with a maximally stimulatory dose of a GHRH analogue resulted to an enhancing effect of the GHRH-induced GH release, suggesting that other mechanisms are also implicated⁹³. Data on possible sex differences are contradictory. Naloxone infusion decreased the growth hormone-releasing hormone (GHRH)-induced GH release in healthy women but had no effect in normal men⁹⁶. On the other hand, in another study, naloxone significantly blunted the GH response to GHRH in healthy male volunteers⁹⁷.

Humans treated with intrathecal opioids (morphine and hydromorphone) for non-malignant pain had significantly lower serum insulin-like growth factor 1 (IGF-1) levels compared with controls; 17% of the subjects had IGF-1 concentrations more than two standard deviations below the mean, whilst 15% of them showed peak GH $<3 \mu\text{g/L}$ during ITT¹⁶. Abnormal GH response on ITT was also detected in 26% of methadone-treated patients and in 31% of heroin addicts⁹⁸. In this study, a maximal level of GH $>9 \mu\text{g/L}$ or an increment over the baseline $>10 \mu\text{g/L}$ were defined as criteria of a normal response; using the cut-off of $<3 \mu\text{g/L}$, a compromised GH response would be found in 5% and 6% of methadone and heroin users, respectively. Finally, chronic pain patients on oral opioids had no abnormal IGF-1 levels or a difference in GH response to the glucagon stimulation test when compared to a control group receiving non-opioid analgesia⁹⁹; a suboptimal GH response found in two cases was finally attributed to obesity.

The above data demonstrate the complexity of the effects and relevant mechanisms of opioids on the GH axis. Overall, acute administration of opioids increases GH secretion but the impact of chronic use varies considerably. Gender, opioid type, route and dose are factors that influence the action of opioids on GH release. The clinical significance of these findings in patients using long-term opioids remains to be elucidated.

Prolactin

Opioids can have a stimulatory effect on PRL secretion mediated by μ -, κ - and δ -opioid receptors in the hypothalamus¹⁰⁰.

Acute administration (oral or intravenous) of morphine increases PRL in healthy men¹⁰¹ and postmenopausal women⁹⁴. In women, sex steroids may alter the opioid-induced effects on PRL secretion; thus, whilst naloxone had no effect on PRL secretion in postmenopausal and hypogonadal women, as well as women in the early follicular phase of the menstrual cycle, when administered for 7 days in the luteal phase, it induced PRL release⁹.

In chronic use of opioids, the effects are variable. PRL levels have been found high in opioid addicted subjects and in opium smokers^{18, 102, 103}. Furthermore, oral opioids for chronic pain increase PRL^{104, 105}. On the other hand, morphine offered intrathecally for chronic non-cancer pain had no effect on PRL¹⁶. Finally, buprenorphine or methadone maintenance therapy for opioid dependence did not lead to high PRL^{34, 106}.

Opioid-induced hyperprolactinaemia can lead to painful gynecomastia, galactorrhoea and hypogonadism¹⁰⁴.

Bromocriptine has been successfully used in cases of hyperprolactinaemia due to opioid use¹⁰⁷.

Overall, high PRL can be detected in patients on opioids, although the effect of pain on this finding needs to be taken into account. The frequency of hyperprolactinaemia and the impact of dose, route and type of drug have not been clearly established, but the clinician needs to be aware of this potential consequence and its clinical sequelae (particularly on the gonadotroph axis).

Hypothalamo-pituitary-thyroid axis

Based on most animal studies, opioids have inhibitory effect on thyroid-stimulating hormone (TSH) secretion and this is observed mainly with pharmacological doses^{108, 109}.

In humans, acute intravenous administration of morphine in normal volunteers led to a significant increase in serum TSH and enhanced the response of TSH to thyrotropin-releasing hormone stimulation¹¹⁰.

In chronic use of opioids for cancer pain and in opioid addicts, there was no difference in basal levels of TSH and peripheral thyroid hormones compared with from controls^{16, 104, 111, 112}. However, opium smokers had lower TSH levels compared with healthy volunteers¹⁰².

The potential clinical significance and the implications of these data remain to be elucidated and, therefore, at this stage, clinical recommendations cannot be provided.

Arginine Vasopressin

Opioids affect arginine vasopressin (AVP) secretion through μ -¹¹³ and possibly κ -opioid receptors¹¹⁴.

Acute opioid administration can lead to a rise in AVP levels. Fentanyl offered in two continuous intravenous infusions in five healthy volunteers increased plasma AVP in a dose-dependent manner¹¹⁵. Notably, a case of a patient on fentanyl patches who developed syndrome of inappropriate antidiuretic hormone secretion has been published¹¹⁶.

Boulton *et al.* showed that in patients undergoing coronary artery bypass surgery, the levels of AVP were significantly higher with fentanyl than with sufentanil during induction of anaesthesia¹¹⁷. Administration of extradural injection of morphine six hours after surgery in six patients produced increase in plasma AVP¹¹⁸. Bozkurt *et al.*, in a series of children undergoing surgery (major genito-urinary or abdominal operations), found that both a single dose of epidural morphine post-induction or morphine infusion led to increase in serum ADH levels¹¹⁹.

Overall, the studies on the impact of exogenous opioids on AVP in humans are confounded by the differences in the fluid status of the subjects, as well as by the side effects of opioids, including hypotension and nausea, which can stimulate AVP release. Therefore, the interpretation of the published data and the extraction of robust conclusions for clinical practice remain challenging.

Bone Mineral Density and Fracture Risk

Exogenous opioids have a negative impact on bone health. Opioid-induced hypogonadism, as well as direct action of these drugs on bone formation are potential contributing factors. Osteoblasts express opioid receptors and opioids inhibit the growth of human osteoblast tissue cultures; this effect was prevented by opioid antagonists¹²⁰. Furthermore, opioids inhibit osteocalcin production in osteoblast tissue cultures¹²⁰.

Male chronic heroin users have significantly lower vertebral bone mineral density (BMD) compared with healthy age- and sex-matched control subjects¹²¹. In a cross-sectional study of patients taking methadone maintenance therapy, BMD was lower from control values throughout the skeleton in men but not in women; notably in this series, the male patients had lower serum testosterone than

the controls¹²². In another study, 50% of men and 21% of women on chronic oral opioids had osteopenia; in this report, however, males had used opioids for a longer period and had higher prevalence of hypogonadism compared with women¹⁵. In addition, in a study of 14 males on intrathecal opioids for chronic non-malignant pain and hypogonadism, osteoporosis was observed in 21% and osteopenia in 50%²⁵. In a cross-sectional analysis of adults aged 17 years and older from the Third National Health and Nutrition Examination Survey, opioids were associated with significantly reduced BMD besides anticonvulsants¹²³.

In a case control study from a nation-wide register in Denmark, there was increased fracture risk in users of morphine and other opioids¹²⁴. Notably, the authors suggested that this increase, which was observed even on very low doses, may be related with the risk of falls owing to the acute central nervous system effects of opioids¹²⁴. This view was further supported by a nested case-control study using the UK-based General Practice Research Database in which a clear dose-response relationship between current cumulative opioid use and risk of fracture was found¹²⁵; thus, current light use of opioids was associated with increased the risk of fractures in adults with non-cancer pain, particularly during the initial weeks of administration, whilst current heavy cumulative opioid use was not, particularly in women¹²⁵. Finally, the contribution of limitations in mobility (due to chronic pain) on the higher risk of fractures cannot be excluded.

There is no consensus on the monitoring of the BMD in patients on opioids but those with risk factors and particularly hypogonadism require assessment. Discontinuing the opioid, if possible, and treatment of osteoporosis or osteopenia according to the current guidelines are management approaches.

Conclusions and future perspectives

Exogenous opioids have effects on multiple levels of the endocrine system through mechanisms which are still not fully elucidated (Table 2). Hypogonadism is the most well recognised consequence of opioid use which, however, may remain undiagnosed with potential adverse sequelae for the patients. Although less frequent, cortisol deficiency can be found. The data on the impact of opioids

on GH and TSH are less clear and often complex, whereas hyperprolactinaemia can be occasionally detected. AVP levels may be increased in patients on these drugs but a number of confounding factors do not allow clear conclusions to be drawn. Of particular importance is the negative impact of opioids on bone health, which may be overlooked during the care of these patients.

Discontinuation or reduction of the opioid and, in cases of chronic pain, consideration of alternative therapies for pain relief are potential management options. Hormonal replacement, especially when the above measures are not practically feasible, needs to be considered (Table 2). Awareness of the endocrine effects of opioids by all specialists prescribing or managing patients on these drugs is vital, particularly given the expanding dimensions of this problem as a global epidemic.

Further research is needed to clearly establish the prevalence of hormonal abnormalities with various regimes, doses and routes of opioids, the impact of partial agonists (like buprenorphine) and the clinical significance of the biochemical findings from the HPA axis. Finally, well designed prospective rather than cross-sectional studies taking into account the effect of confounding factors (like other co-morbidities, drugs or pain) are needed to clarify the long-term benefits and risks of hormonal treatment and its effects on other areas, including pain sensitivity and potential reduction in opioid dose, and recovery of patients on methadone for opioid use disorder. These will finally lead to safe and cost-effective clinical guidelines, but until these become available, periodical assessment of the gonadal and adrenal function (particularly when relevant clinical manifestations are present) and evaluation of bone health status are advised.

Declaration of interest

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References

1. Pathan H & Williams J. Basic opioid pharmacology: an update. *British Journal of Pain* 2012 **6** 11-16.
2. Dietis N, Rowbotham DJ & Lambert DG. Opioid receptor subtypes: fact or artifact? *British Journal of Anaesthesia* 2011 **107** 8-18.
3. Stein C. Opioid Receptors. *Annual Review of Medicine* 2016 **67** 433-451.
4. McDonald J & Lambert DG. Opioid receptors. *BJA Education* 2015 **15** 219-224.
5. Manchikanti L, Kaye AM, Knezevic NN, McAnally H, Slavin K, Trescot AM, Blank S, Pampati V, Abdi S, Grider JS, et al. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. *Pain Physician* 2017 **20** S3-s92.
6. Zin CS, Chen LC & Knaggs RD. Changes in trends and pattern of strong opioid prescribing in primary care. *European Journal of Pain (London, England)* 2014 **18** 1343-1351.
7. Ray WA, Chung CP, Murray KT, Hall K & Stein CM. Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain. *JAMA* 2016 **315** 2415-2423.
8. Grossman A, Moulton PJ, Cunnah D & Besser M. Different opioid mechanisms are involved in the modulation of ACTH and gonadotrophin release in man. *Neuroendocrinology* 1986 **42** 357-360.
9. Vuong C, Van Uum SH, O'Dell LE, Lutfy K & Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. *Endocrine Reviews* 2010 **31** 98-132.
10. Mendelson JH, Ellingboe J, Judson BA & Goldstein A. Plasma testosterone and luteinizing hormone levels during levo-alpha-acetylmethadol maintenance and withdrawal. *Clinical Pharmacology and Therapeutics* 1984 **35** 545-547.
11. Woody G, McLellan AT, O'Brien C, Persky H, Stevens G, Arndt I & Carroff S. Hormone secretion in methadone-dependent and abstinent patients. *NIDA Research Monograph* 1988 **81** 216-223.

- 472 12. Roberts LJ, Finch PM, Pullan PT, Bhagat CI & Price LM. Sex hormone suppression by
473 intrathecal opioids: a prospective study. *Clinical Journal of Pain* 2002 **18** 144-148.
- 474 13. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. *Journal of Pain*
475 2002 **3** 377-384.
- 476 14. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action
477 opioids for control of nonmalignant pain. *Journal of Pain* 2008 **9** 28-36.
- 478 15. Fraser LA, Morrison D, Morley-Forster P, Paul TL, Tokmakejian S, Larry Nicholson R,
479 Bureau Y, Friedman TC & Van Uum SH. Oral opioids for chronic non-cancer pain: higher
480 prevalence of hypogonadism in men than in women. *Experimental and Clinical*
481 *Endocrinology and Diabetes* 2009 **117** 38-43.
- 482 16. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, Verlooy J, Van
483 Havenbergh T, Smet M & Van Acker K. Endocrine consequences of long-term intrathecal
484 administration of opioids. *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 2215-
485 2222.
- 486 17. Santen FJ, Sofsky J, Bilic N & Lippert R. Mechanism of action of narcotics in the production
487 of menstrual dysfunction in women. *Fertility and Sterility* 1975 **26** 538-548.
- 488 18. Ragni G, De Lauretis L, Bestetti O, Sghedoni D & Gambaro V. Gonadal function in male
489 heroin and methadone addicts. *International Journal of Andrology* 1988 **11** 93-100.
- 490 19. Bawor M, Bami H, Dennis BB, Plater C, Worster A, Varenbut M, Daiter J, Marsh DC,
491 Steiner M, Anglin R, et al. Testosterone suppression in opioid users: a systematic review and
492 meta-analysis. *Drug and Alcohol Dependence* 2015 **149** 1-9.
- 493 20. Cicero TJ, Bell RD, Wiest WG, Allison JH, Polakoski K & Robins E. Function of the male
494 sex organs in heroin and methadone users. *New England Journal of Medicine* 1975 **292** 882-
495 887.
- 496 21. Mendelson JH & Mello NK. Plasma testosterone levels during chronic heroin use and
497 protracted abstinence. A study of Hong Kong addicts. *Clinical Pharmacology and*
498 *Therapeutics* 1975 **17** 529-533.

- 499 22. Mendelson JH, Mendelson JE & Patch VD. Plasma testosterone levels in heroin addiction and
500 during methadone maintenance. *Journal of Pharmacology and Experimental Therapeutics*
501 1975 **192** 211-217.
- 502 23. Mendelson JH, Inturrisi CE, Renault P & Senay EC. Effects of acetylmethadol on plasma
503 testosterone. *Clinical Pharmacology and Therapeutics* 1976 **19** 371-374.
- 504 24. Pelosi MA, Sama JC, Caterini H & Kamnetzky HA. Galactorrhea-amenorrhea syndrome
505 associated with heroin addiction. *American Journal of Obstetrics and Gynecology* 1974 **118**
506 966-970.
- 507 25. Duarte RV, Raphael JH, Southall JL, Labib MH, Whallett AJ & Ashford RL. Hypogonadism
508 and low bone mineral density in patients on long-term intrathecal opioid delivery therapy.
509 *BMJ Open* 2013 **3**.
- 510 26. Finch PM, Roberts LJ, Price L, Hadlow NC & Pullan PT. Hypogonadism in patients treated
511 with intrathecal morphine. *Clinical Journal of Pain* 2000 **16** 251-254.
- 512 27. Paice JA, Penn RD & Ryan WG. Altered sexual function and decreased testosterone in
513 patients receiving intraspinal opioids. *Journal of Pain and Symptom Management* 1994 **9** 126-
514 131.
- 515 28. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G & Bruera E. Hypogonadism and
516 sexual dysfunction in male cancer survivors receiving chronic opioid therapy. *Journal of Pain*
517 *and Symptom Management* 2003 **26** 1055-1061.
- 518 29. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G & Bruera E. Symptomatic
519 hypogonadism in male survivors of cancer with chronic exposure to opioids. *Cancer* 2004
520 **100** 851-858.
- 521 30. Aloisi AM, Aurilio C, Bachiocco V, Biasi G, Fiorenzani P, Pace MC, Paci V, Pari G,
522 Passavanti G, Ravaioli L, et al. Endocrine consequences of opioid therapy.
523 *Psychoneuroendocrinology* 2009 **34 Suppl 1** S162-168.
- 524 31. Rubinstein A & Carpenter DM. Elucidating risk factors for androgen deficiency associated
525 with daily opioid use. *American Journal of Medicine* 2014 **127** 1195-1201.

- 526 32. Rubinstein AL, Carpenter DM & Minkoff JR. Hypogonadism in men with chronic pain linked
527 to the use of long-acting rather than short-acting opioids. *Clinical Journal of Pain* 2013 **29**
528 840-845.
- 529 33. Rubinstein AL & Carpenter DM. Association Between Commonly Prescribed Opioids and
530 Androgen Deficiency in Men: A Retrospective Cohort Analysis. *Pain Medicine* 2017 **18** 637-
531 644.
- 532 34. Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D & Klingmuller D.
533 Plasma testosterone and sexual function in men receiving buprenorphine maintenance for
534 opioid dependence. *Journal of Clinical Endocrinology and Metabolism* 2005 **90** 203-206.
- 535 35. Hallinan R, Byrne A, Agho K, McMahon C, Tynan P & Attia J. Erectile dysfunction in men
536 receiving methadone and buprenorphine maintenance treatment. *Journal of Sexual Medicine*
537 2008 **5** 684-692.
- 538 36. Policola C, Stokes V, Karavitaki N & Grossman A. Adrenal insufficiency in acute oral opiate
539 therapy. *Endocrinology Diabetes and Metabolism Case Reports* 2014 **2014** 130071.
- 540 37. Mussig K, Knaus-Dittmann D, Schmidt H, Morike K & Haring HU. Secondary adrenal
541 failure and secondary amenorrhoea following hydromorphone treatment. *Clinical*
542 *Endocrinology* 2007 **66** 604-605.
- 543 38. Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R & Samuels MH.
544 Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice
545 Guideline. *Journal of Clinical Endocrinology and Metabolism* 2016 **101** 3888-3921.
- 546 39. Aloisi AM, Ceccarelli I, Carlucci M, Suman A, Sindaco G, Mameli S, Paci V, Ravaioli L,
547 Passavanti G, Bachiooco V, et al. Hormone replacement therapy in morphine-induced
548 hypogonadic male chronic pain patients. *Reproductive Biology and Endocrinology* 2011 **9** 26.
- 549 40. Daniell HW, Lentz R & Mazer NA. Open-label pilot study of testosterone patch therapy in
550 men with opioid-induced androgen deficiency. *Journal of Pain* 2006 **7** 200-210.
- 551 41. Basaria S, Travison TG, Alford D, Knapp PE, Teeter K, Cahalan C, Eder R, Lakshman K,
552 Bachman E, Mensing G, et al. Effects of testosterone replacement in men with opioid-induced
553 androgen deficiency: a randomized controlled trial. *Pain* 2015 **156** 280-288.

42. Huang G, Travison T, Maggio M, Edwards RR & Basaria S. Effects of testosterone replacement on metabolic and inflammatory markers in men with opioid-induced androgen deficiency. *Clinical Endocrinology* 2016 **85** 232-238.
43. Glahn A, Heberlein A, Dursteler-MacFarland KM, Lenz B, Frieling H, Groschl M, Wiesbeck GA, Kornhuber J, Bonsch D, Bleich S, et al. Atrial natriuretic peptide, arginine vasopressin peptide and cortisol serum levels in opiate-dependent patients. *Neuropsychobiology* 2013 **67** 111-115.
44. Tsagarakis S, Navarra P, Rees LH, Besser M, Grossman A & Navara P. Morphine directly modulates the release of stimulated corticotrophin-releasing factor-41 from rat hypothalamus in vitro. *Endocrinology* 1989 **124** 2330-2335.
45. Allolio B, Schulte HM, Deuss U, Kallabis D, Hamel E & Winkelman W. Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone. *Acta Endocrinologica* 1987 **114** 509-514.
46. Rittmaster RS, Cutler GB, Jr., Sobel DO, Goldstein DS, Koppelman MC, Loriaux DL & Chrousos GP. Morphine inhibits the pituitary-adrenal response to ovine corticotropin-releasing hormone in normal subjects. *Journal of Clinical Endocrinology and Metabolism* 1985 **60** 891-895.
47. Conaglen JV, Donald RA, Espiner EA, Livesey JH & Nicholls MG. Effect of naloxone on the hormone response to CRF in normal man. *Endocrine Research* 1985 **11** 39-44.
48. Schluger JH, Ho A, Borg L, Porter M, Maniar S, Gunduz M, Perret G, King A & Kreek MJ. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. *Alcoholism, Clinical and Experimental Research* 1998 **22** 1430-1436.
49. Pfeiffer A, Knepel W, Braun S, Meyer HD, Lohmann H & Brantl V. Effects of a kappa-opioid agonist on adrenocorticotrophic and diuretic function in man. *Hormone and Metabolic Research* 1986 **18** 842-848.
50. Napier C, Gan EH & Pearce SH. Loperamide-induced hypopituitarism. *BMJ Case Reports* 2016 **2016**.

51. Lee AS & Twigg SM. Opioid-induced secondary adrenal insufficiency presenting as hypercalcaemia. *Endocrinology Diabetes and Metabolism Case Reports* 2015 **2015** 150035.
52. Das G. Chronic heroin dependence leading to adrenal insufficiency. *Case Reports in Endocrinology* 2014 **2014** 461816.
53. Debono M, Chan S, Rolfe C & Jones TH. Tramadol-induced adrenal insufficiency. *European Journal of Clinical Pharmacology* 2011 **67** 865-867.
54. Oltmanns KM, Fehm HL & Peters A. Chronic fentanyl application induces adrenocortical insufficiency. *Journal of Internal Medicine* 2005 **257** 478-480.
55. Ducat E, Ray B, Bart G, Umemura Y, Varon J, Ho A & Kreek MJ. Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotrophic hormone stress response to metyrapone. *Addiction Biology* 2013 **18** 325-331.
56. Chong RY, Oswald L, Yang X, Uhart M, Lin PI & Wand GS. The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. *Neuropsychopharmacology* 2006 **31** 204-211.
57. Coiro V, Volpi R, Stella A, Venturi N & Chiodera P. Stimulatory effect of naloxone on plasma cortisol in human: Possible direct stimulatory action at the adrenal cortex. *Regulatory Peptides* 2011 **166** 1-2.
58. Clarke D, Fearon U, Cunningham SK & McKenna TJ. The steroidogenic effects of beta-endorphin and joining peptide: a potential role in the modulation of adrenal androgen production. *Journal of Endocrinology* 1996 **151** 301-307.
59. el Daly ES. Influence of acute and chronic morphine or stadol on the secretion of adrenocorticotrophin and its hypothalamic releasing hormone in the rat. *Life Sciences* 1996 **59** 1881-1890.
60. Buckingham JC & Cooper TA. Differences in hypothalamo-pituitary-adrenocortical activity in the rat after acute and prolonged treatment with morphine. *Neuroendocrinology* 1984 **38** 411-417.

61. Radahmadi M, Sharifi MR, Amini M & Fesharaki M. Effect of the co-administration of glucose with morphine on glucoregulatory hormones and causing of diabetes mellitus in rats. *Advanced Biomedical Research* 2016 **5** 21.
62. Ferenczi S, Nunez C, Pinter-Kubler B, Foldes A, Martin F, Markus VL, Milanes MV & Kovacs KJ. Changes in metabolic-related variables during chronic morphine treatment. *Neurochemistry International* 2010 **57** 323-330.
63. Bershad AK, Jaffe JH, Childs E & de Wit H. Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans. *Psychoneuroendocrinology* 2015 **52** 281-288.
64. Watanabe K, Kashiwagi K, Kamiyama T, Yamamoto M, Fukunaga M, Inada E & Kamiyama Y. High-dose remifentanyl suppresses stress response associated with pneumoperitoneum during laparoscopic colectomy. *Journal of Anesthesia* 2014 **28** 334-340.
65. Facchinetti F, Volpe A, Farci G, Petraglia F, Porro CA, Barbieri G, Cioni A, Balestrieri A & Genazzani AR. Hypothalamus-pituitary-adrenal axis of heroin addicts. *Drug and Alcohol Dependence* 1985 **15** 361-366.
66. Lavallo WR, King AC, Farag NH, Sorocco KH, Cohoon AJ & Vincent AS. Naltrexone effects on cortisol secretion in women and men in relation to a family history of alcoholism: studies from the Oklahoma Family Health Patterns Project. *Psychoneuroendocrinology* 2012 **37** 1922-1928.
67. Roche DJ, Childs E, Epstein AM & King AC. Acute HPA axis response to naltrexone differs in female vs. male smokers. *Psychoneuroendocrinology* 2010 **35** 596-606.
68. Uhart M, Chong RY, Oswald L, Lin PI & Wand GS. Gender differences in hypothalamic-pituitary-adrenal (HPA) axis reactivity. *Psychoneuroendocrinology* 2006 **31** 642-652.
69. Roche DJ & King AC. Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase. *Psychoneuroendocrinology* 2015 **52** 59-71.
70. Gerber H, Borgwardt SJ, Schmid O, Gerhard U, Joechle W, Riecher-Rossler A, Wiesbeck GA & Walter M. The impact of diacetylmorphine on hypothalamic-pituitary-adrenal axis activity and heroin craving in heroin dependence. *European Addiction Research* 2012 **18** 116-123.

- 636 71. Facchinetti F, Grasso A, Petraglia F, Parrini D, Volpe A & Genazzani AR. Impaired circadian
637 rhythmicity of beta-lipotrophin, beta-endorphin and ACTH in heroin addicts. *Acta*
638 *Endocrinologica* 1984 **105** 149-155.
- 639 72. McCain GA & Tilbe KS. Diurnal hormone variation in fibromyalgia syndrome: a comparison
640 with rheumatoid arthritis. *Journal of Rheumatology. Supplement* 1989 **19** 154-157.
- 641 73. Griep EN, Boersma JW, Lentjes EG, Prins AP, van der Korst JK & de Kloet ER. Function of
642 the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain.
643 *Journal of Rheumatology* 1998 **25** 1374-1381.
- 644 74. Gibb FW, Stewart A, Walker BR & Strachan MW. Adrenal insufficiency in patients on long-
645 term opioid analgesia. *Clinical Endocrinology* 2016 **85** 831-835.
- 646 75. Valverde-Filho J, da Cunha Neto MB, Fonoff ET, Meirelles Ede S & Teixeira MJ. Chronic
647 spinal and oral morphine-induced neuroendocrine and metabolic changes in noncancer pain
648 patients. *Pain Medicine* 2015 **16** 715-725.
- 649 76. Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids:
650 evidence for opioid-induced inhibition of adrenal androgen production. *Journal of Pain* 2006
651 **7** 901-907.
- 652 77. Nenke MA, Haylock CL, Rankin W, Inder WJ, Gagliardi L, Eldridge C, Rolan P & Torpy DJ.
653 Low-dose hydrocortisone replacement improves wellbeing and pain tolerance in chronic pain
654 patients with opioid-induced hypocortisolemic responses. A pilot randomized, placebo-
655 controlled trial. *Psychoneuroendocrinology* 2015 **56** 157-167.
- 656 78. Singh M, Simpkins JW, Layden MP, Romano TM & Millard WJ. Opiate modulation of
657 growth hormone secretion is compromised during the steroid-induced luteinizing hormone
658 surge. *Neuroendocrinology* 1992 **55** 214-220.
- 659 79. Bartolome MB & Kuhn CM. Endocrine effects of methadone in rats; acute effects in adults.
660 *European Journal of Pharmacology* 1983 **95** 231-238.
- 661 80. Armstrong JD & Spears JW. Changes in growth hormone and luteinizing hormone following
662 acute or chronic administration of an opioid agonist, FK33-824, in wethers. *Journal of Animal*
663 *Science* 1991 **69** 774-781.

- 664 81. Ceger P & Kuhn CM. Opiate withdrawal in the neonatal rat: relationship to duration of
665 treatment and naloxone dose. *Psychopharmacology* 2000 **150** 253-259.
- 666 82. Muller EE, Locatelli V & Cocchi D. Neuroendocrine control of growth hormone secretion.
667 *Physiological Reviews* 1999 **79** 511-607.
- 668 83. Eason MG, Francis RS & Kuhn CM. mu-Opioid agonists stimulate growth hormone secretion
669 in immature rats. *Neuroendocrinology* 1996 **63** 489-497.
- 670 84. Janik J, Klosterman S, Parman R & Callahan P. Multiple opiate receptor subtypes are
671 involved in the stimulation of growth hormone release by beta-endorphin in female rats.
672 *Neuroendocrinology* 1994 **60** 69-75.
- 673 85. Willoughby JO & Medvedev A. Opioid receptor activation resets the hypothalamic clock
674 generating growth hormone secretory bursts in the rat. *Journal of Endocrinology* 1996 **148**
675 149-155.
- 676 86. Miki N, Ono M & Shizume K. Evidence that opiate and alpha-adrenergic mechanisms
677 stimulate rat growth hormone release via growth hormone-releasing factor (GRF).
678 *Endocrinology* 1984 **114** 1950-1952.
- 679 87. Wehrenberg WB, Bloch B & Ling N. Pituitary secretion of growth hormone in response to
680 opioid peptides and opiates is mediated through growth hormone-releasing factor.
681 *Neuroendocrinology* 1985 **41** 13-16.
- 682 88. Drouva SV, Epelbaum J, Tapia-Arancibia L, Laplante E & Kordon C. Opiate receptors
683 modulate LHRH and SRIF release from mediobasal hypothalamic neurons.
684 *Neuroendocrinology* 1981 **32** 163-167.
- 685 89. Borer KT, Nicoski DR & Owens V. Alteration of pulsatile growth hormone secretion by
686 growth-inducing exercise: involvement of endogenous opiates and somatostatin.
687 *Endocrinology* 1986 **118** 844-850.
- 688 90. Dobado-Berrios PM, Li S, Garcia de Yebenes E & Pelletier G. Effects of morphine and
689 naloxone on prolactin and growth hormone gene expression in the male rat pituitary gland.
690 *Journal of Neuroendocrinology* 1993 **5** 553-556.

91. Simpkins JW, Millard WJ & Berglund LA. Effects of chronic stimulation or antagonism of opiate receptors on GH secretion in male and female rats. *Life Sciences* 1993 **52** 1443-1450.
92. Bhansali A, Velayutham P, Sialy R & Sethi B. Effect of opiates on growth hormone secretion in acromegaly. *Hormone and Metabolic Research* 2005 **37** 425-427.
93. Delitala G, Tomasi PA, Palermo M, Ross RJ, Grossman A & Besser GM. Opioids stimulate growth hormone (GH) release in man independently of GH-releasing hormone. *Journal of Clinical Endocrinology and Metabolism* 1989 **69** 356-358.
94. Hemmings R, Fox G & Tolis G. Effect of morphine on the hypothalamic-pituitary axis in postmenopausal women. *Fertility and Sterility* 1982 **37** 389-391.
95. Tolis G, Hickey J & Guyda H. Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. *Journal of Clinical Endocrinology and Metabolism* 1975 **41** 797-800.
96. Barbarino A, De Marinis L, Mancini A, D'Amico C, Passeri M, Zuppi P, Sambo P & Tofani A. Sex-related naloxone influence on growth hormone-releasing hormone-induced growth hormone secretion in normal subjects. *Metabolism: Clinical and Experimental* 1987 **36** 105-109.
97. Tomasi PA, Fanciulli G, Palermo M, Pala A, Demontis MA & Delitala G. Opioid-receptor blockade blunts growth hormone (GH) secretion induced by GH-releasing hormone in the human male. *Hormone and Metabolic Research* 1998 **30** 34-36.
98. Cushman P, Jr. Growth hormone in narcotic addiction. *Journal of Clinical Endocrinology and Metabolism* 1972 **35** 352-358.
99. Merza Z, Edwards N, Walters SJ, Newell-Price J & Ross RJ. Patients with chronic pain and abnormal pituitary function require investigation. *Lancet* 2003 **361** 2203-2204.
100. Dobson PR & Brown BL. Involvement of the hypothalamus in opiate-stimulated prolactin secretion. *Regulatory Peptides* 1988 **20** 305-310.
101. Delitala G, Grossman A & Besser GM. The participation of hypothalamic dopamine in morphine-induced prolactin release in man. *Clinical Endocrinology* 1983 **19** 437-444.

- 718 102. Moshtaghi-Kashanian GR, Esmaeeli F & Dabiri S. Enhanced prolactin levels in opium
719 smokers. *Addiction Biology* 2005 **10** 345-349.
- 720 103. Chan V, Wang C & Yeung RT. Effects of heroin addiction on thyrotrophin, thyroid hormones
721 and prolactin secretion in men. *Clinical Endocrinology* 1979 **10** 557-565.
- 722 104. Rhodin A, Stridsberg M & Gordh T. Opioid endocrinopathy: a clinical problem in patients
723 with chronic pain and long-term oral opioid treatment. *Clinical Journal of Pain* 2010 **26** 374-
724 380.
- 725 105. Wong D, Gray DP, Simmonds M, Rashid S, Sobolev I & Morrish DW. Opioid analgesics
726 suppress male gonadal function but opioid use in males and females does not correlate with
727 symptoms of sexual dysfunction. *Pain Research and Management* 2011 **16** 311-316.
- 728 106. de la Rosa RE & Hennessey JV. Hypogonadism and methadone: Hypothalamic
729 hypogonadism after long-term use of high-dose methadone. *Endocrine Practice* 1996 **2** 4-7.
- 730 107. Vescovi PP, Pezzarossa A, Ceresini G, Rastelli G, Valenti G & Gerra G. Effects of dopamine
731 receptor stimulation on opiate-induced modifications of pituitary-gonadal function. *Hormone*
732 *Research* 1985 **21** 155-159.
- 733 108. Judd AM & Hedge GA. The roles of opioid peptides in controlling thyroid stimulating
734 hormone release. *Life Sciences* 1982 **31** 2529-2536.
- 735 109. del Valle-Soto ME, Iglesias L, Calzada B, Vega JA, Hernandez LC & Perez-Casas A. Effects
736 of morphine on the pituitary-thyroid axis: morphological and analytical studies. *Functional*
737 *and Developmental Morphology* 1991 **1** 3-6.
- 738 110. Devilla L, Pende A, Morgano A, Giusti M, Musso NR & Lotti G. Morphine-induced TSH
739 release in normal and hypothyroid subjects. *Neuroendocrinology* 1985 **40** 303-308.
- 740 111. Brambilla F, Nobile P, Zanoboni A, Zanoboni-Muciaccia W & Meroni PL. Effects of chronic
741 heroin addiction on pituitary-thyroid function in man. *Journal of Endocrinological*
742 *Investigation* 1980 **3** 251-255.
- 743 112. Merdin A, Merdin FA, Gunduz S, Bozcuk H & Coskun HS. Opioid endocrinopathy: A
744 clinical problem in patients with cancer pain. *Experimental and Therapeutic Medicine* 2016
745 **11** 1819-1822.

- 746 113. Zerbe RL, Henry DP & Robertson GL. A new Met-enkephalin analogue suppresses plasma
747 vasopressin in man. *Peptides* 1982 **3** 199-201.
- 748 114. Kramer HJ, Uhl W, Ladstetter B & Backer A. Influence of asimadoline, a new kappa-opioid
749 receptor agonist, on tubular water absorption and vasopressin secretion in man. *British*
750 *Journal of Clinical Pharmacology* 2000 **50** 227-235.
- 751 115. Weiskopf RB, Reid IA, Fisher DM, Holmes MA, Rosen JI & Keil LC. Effects of fentanyl on
752 vasopressin secretion in human subjects. *Journal of Pharmacology and Experimental*
753 *Therapeutics* 1987 **242** 970-973.
- 754 116. Kokko H, Hall PD & Afrin LB. Fentanyl-associated syndrome of inappropriate antidiuretic
755 hormone secretion. *Pharmacotherapy* 2002 **22** 1188-1192.
- 756 117. Boulton AJ, Wilson N, Turnbull KW & Yip RW. Haemodynamic and plasma vasopressin
757 responses during high-dose fentanyl or sufentanil anaesthesia. *Canadian Anaesthetists Society*
758 *Journal* 1986 **33** 475-483.
- 759 118. Korinek AM, Languille M, Bonnet F, Thibonnier M, Sasano P, Lienhart A & Viars P. Effect
760 of postoperative extradural morphine on ADH secretion. *British Journal of Anaesthesia* 1985
761 **57** 407-411.
- 762 119. Bozkurt P, Kaya G, Yeker Y, Altintas F, Bakan M, Hacibekiroglu M & Kavunoglu G. Effects
763 of systemic and epidural morphine on antidiuretic hormone levels in children. *Paediatric*
764 *Anaesthesia* 2003 **13** 508-514.
- 765 120. Daniell HW. Opioid osteoporosis. *Archives of Internal Medicine* 2004 **164** 338; author reply
766 338.
- 767 121. Pedrazzoni M, Vescovi PP, Maninetti L, Michelini M, Zaniboni G, Pioli G, Costi D, Alfano
768 FS & Passeri M. Effects of chronic heroin abuse on bone and mineral metabolism. *Acta*
769 *Endocrinologica* 1993 **129** 42-45.
- 770 122. Grey A, Rix-Trott K, Horne A, Gamble G, Bolland M & Reid IR. Decreased bone density in
771 men on methadone maintenance therapy. *Addiction* 2011 **106** 349-354.
- 772 123. Kinjo M, Setoguchi S, Schneeweiss S & Solomon DH. Bone mineral density in subjects using
773 central nervous system-active medications. *American Journal of Medicine* 2005 **118** 1414.

- 774 124. Vestergaard P, Rejnmark L & Mosekilde L. Fracture risk associated with the use of morphine
775 and opiates. *Journal of Internal Medicine* 2006 **260** 76-87.
- 776 125. Li L, Setoguchi S, Cabral H & Jick S. Opioid use for noncancer pain and risk of fracture in
777 adults: a nested case-control study using the general practice research database. *American*
778 *Journal of Epidemiology* 2013 **178** 559-569.
- 779
- 780
- 781
- 782
- 783
- 784